Cutler Group LP Blueprint Medicines Corp Put Options Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2023 Jul 18, 2023	BUY	$42.2 - $66.37 $105,500 - $165,925	2,500 New	2,500 $0
Q1 2022 Apr 14, 2022	SELL	$54.1 - $110.08 $64,920 - $132,096	-1,200 Reduced 23.08%	4,000 $20,000
Q3 2020 Oct 27, 2020	BUY	$66.45 - $92.7 $232,575 - $324,450	3,500 Added 205.88%	5,200 $29,000
Q4 2019 Feb 06, 2020	SELL	$66.73 - $82.59 $667,300 - $825,900	-10,000 Reduced 85.47%	1,700 $33,000
Q3 2019 Oct 28, 2019	BUY	$72.9 - $101.41 $663,390 - $922,831	9,100 Added 350.0%	11,700 $116,000
Q2 2019 Aug 09, 2019	SELL	$73.54 - $97.8 $176,496 - $234,720	-2,400 Reduced 48.0%	2,600 $31,000
Q1 2019 May 10, 2019	BUY	$48.7 - $86.6 $121,750 - $216,500	2,500 Added 100.0%	5,000 $40,000
Q4 2018 Feb 05, 2019	SELL	$45.57 - $74.26 $22,785 - $37,130	-500 Reduced 16.67%	2,500 $69,000
Q1 2018 May 11, 2018	BUY	$73.28 - $102.95 $219,840 - $308,850	3,000 New	3,000 $18,000

362

62.7M

2.24M

1.15M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.18B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.